Neurocrine Biosciences (NBIX) 2024 Wells Fargo Healthcare Conference summary

Leadership transition and strategic vision

• CEO-elect Kyle Gano will assume leadership in 36 days, emphasizing continuity and growth.

• Focus on a diversified, sustainable pipeline with internal R&D transformation reducing reliance on external assets.

• Financial strength highlighted by $1.7 billion in cash, supporting ongoing investment and expansion.

• Commitment to developing more medicines and maintaining operational excellence.

Pipeline and portfolio development

• INGREZZA continues strong growth, with $580 million in Q2 revenue and significant market opportunity remaining.

• Crinecerfont, a first-in-class CRF1 antagonist, received breakthrough designation and has two PDUFA dates at the end of 2024.

• Five programs in phase I, including gene therapy, are advancing, with a focus on disease modification and curative therapies.

• Portfolio includes both internal research and selective business development, balancing risk and opportunity.

Muscarinic and DAAO inhibitor program updates

• Positive phase II results for selective M4 agonist NBI-568, with strong efficacy and safety at 20 mg once daily.

• Plans to initiate phase III schizophrenia trials and explore additional indications in 2025.

• Luvadaxistat, a DAAO inhibitor, showed promising cognition results in phase II; a replicate study is underway with results expected soon.